LIMD2 targeted by miR‑34a promotes the proliferation and invasion of non‑small cell lung cancer cells

Wang,Fei; Li,Zhaoguo; Xu,Lei; Li,Yongchao; Li,Yi; Zhang,Xingbo; Wang,Yue; Liu,Dazhong

doi:10.3892/mmr.2018.9464

LIMD2 targeted by miR‑34a promotes the proliferation and invasion of non‑small cell lung cancer cells

Authors:
- Fei Wang
- Zhaoguo Li
- Lei Xu
- Yongchao Li
- Yi Li
- Xingbo Zhang
- Yue Wang
- Dazhong Liu
View Affiliations

Affiliations: Department of Thoracic Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China, Department of Pulmonary, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China, Department of Medical, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China, Department of Thoracic Surgery, The Fifth People's Hospital of Dalian City, Dalian, Liaoning 116000, P.R. China, Department of Pharmacology and Toxicology, Wright State University, Fairborn, OH 45435, USA
Published online on: September 6, 2018 https://doi.org/10.3892/mmr.2018.9464
Pages: 4760-4766

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A previous study indicated that LIM domain containing 2 (LIMD2) is an oncogene in a variety of human cancers, including breast, bladder and thyroid cancers, and melanoma; however, the role of LIMD2 in non‑small cell lung cancer (NSCLC) remains largely unknown. In the present study, by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) analysis, it was demonstrated that LIMD2 was significantly upregulated in NSCLC tissues compared with adjacent normal tissues. Consistently, LIMD2 was also upregulated in NSCLC cell lines. Furthermore, the present study reported that knockdown of LIMD2 significantly inhibited the proliferation and invasion of H1299 and A549 cells by Cell Counting Kit‑8 and Transwell assays. In addition, the expression of LIMD2 was determined to be regulated by microRNA (miR)‑34a in the present study. RT‑qPCR and western blot analysis indicated that overexpression of miR‑34a notably reduced the mRNA and protein expression levels of LIMD2 in H1299 and H549 cells. Additionally, the present study reported an inverse correlation between the expression of LIMD2 and miR‑34a in NSCLC tissues. A luciferase reporter assay also demonstrated that miR‑34a directly targeted the mRNA expression of LIMD2 in NSCLC cells. Finally, miR‑34a was revealed to possess a tumor suppressive role in NSCLC cells. Collectively, the results of the present study revealed that LIMD2 promoted NSCLC progression and was regulated by miR‑34a.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Ramalingam SS, Owonikoko TK and Khuri FR: Lung cancer: New biological insights and recent therapeutic advances. CA Cancer J Clin. 61:91–112. 2011. View Article : Google Scholar : PubMed/NCBI
3	Paz-Ares L: Beyond first-line NSCLC therapy: Chemotherapy or erlotinib? Lancet Oncol. 13:225–227. 2012. View Article : Google Scholar : PubMed/NCBI
4	Geng GJ, Yang YT, Jiang J, Yu XY and Fa XE: MicroRNA-30a suppresses non-small-cell lung cancer by targeting Myb-related protein B. Exp Ther Med. 15:1633–1639. 2018.PubMed/NCBI
5	Peng H, Talebzadeh-Farrooji M, Osborne MJ, Prokop JW, McDonald PC, Karar J, Hou Z, He M, Kebebew E, Orntoft T, et al: LIMD2 is a small LIM-only protein overexpressed in metastatic lesions that regulates cell motility and tumor progression by directly binding to and activating the integrin-linked kinase. Cancer Res. 74:1390–1403. 2014. View Article : Google Scholar : PubMed/NCBI
6	Cerutti JM, Oler G, Michaluart P Jr, Delcelo R, Beaty RM, Shoemaker J and Riggins GJ: Molecular profiling of matched samples identifies biomarkers of papillary thyroid carcinoma lymph node metastasis. Cancer Res. 67:7885–7892. 2007. View Article : Google Scholar : PubMed/NCBI
7	Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C and Zheng ZM: Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One. 3:e25572008. View Article : Google Scholar : PubMed/NCBI
8	Liu H, Lei C, He Q, Pan Z, Xiao D and Tao Y: Nuclear functions of mammalian MicroRNAs in gene regulation, immunity and cancer. Mol Cancer. 17:642018. View Article : Google Scholar : PubMed/NCBI
9	Xie F, Huang Q, Liu CH, Lin XS, Liu Z, Liu LL, Huang DW and Zhou HC: MiR-1271 negatively regulates AKT/MTOR signaling and promotes apoptosis via targeting PDK1 in pancreatic cancer. Eur Rev Med Pharmacol Sci. 22:678–686. 2018.PubMed/NCBI
10	Xia D, Tian S, Chen Z, Qin W and Liu Q: miR302a inhibits the proliferation of esophageal cancer cells through the MAPK and PI3K/Akt signaling pathways. Oncol Lett. 15:3937–3943. 2018.PubMed/NCBI
11	Xie Y, Zhang H, Guo XJ, Feng YC, He RZ, Li X, Yu S, Zhao Y, Shen M, Zhu F, et al: Let-7c inhibits cholangiocarcinoma growth but promotes tumor cell invasion and growth at extrahepatic sites. Cell Death Dis. 9:2492018. View Article : Google Scholar : PubMed/NCBI
12	Wang N, Zhang Y and Liang H: microRNA-598 inhibits cell proliferation and invasion of glioblastoma by directly targeting metastasis associated in colon cancer-1. Oncol Res. Feb 14–2018.(Epub ahead of print). View Article : Google Scholar
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(-Delta Delta C) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Pinheiro Dos, Santos MJC, Bastos AU, da Costa VR, Delcelo R, Lindsey SC, Colozza-Gama GA, Peng H, Rauscher FJ III, Oler G and Cerutti JM: LIMD2 is overexpressed in BRAF V600E-positive papillary thyroid carcinomas and matched lymph node metastases. Endocr Pathol. 29:222–230. 2018. View Article : Google Scholar : PubMed/NCBI
15	Tong X, Wang X, Wang C and Li L: Elevated levels of serum MiR-152 and miR-24 in uterine sarcoma: Potential for inducing autophagy via SIRT1 and deacetylated LC3. Br J Biomed Sci. 75:7–12. 2018. View Article : Google Scholar : PubMed/NCBI
16	You Y, Tan J, Gong Y, Dai H, Chen H, Xu X, Yang A, Zhang Y and Bie P: MicroRNA-216b-5p Functions as a Tumor-suppressive RNA by Targeting TPT1 in pancreatic cancer cells. J Cancer. 8:2854–2865. 2017. View Article : Google Scholar : PubMed/NCBI
17	Cao J, Yan XR, Liu T, Han XB, Yu JJ, Liu SH and Wang LB: MicroRNA-552 promotes tumor cell proliferation and migration by directly targeting DACH1 via the Wnt/β-catenin signaling pathway in colorectal cancer. Oncol Lett. 14:3795–3802. 2017. View Article : Google Scholar : PubMed/NCBI
18	Zhang M, Huang S and Long D: MiR-381 inhibits migration and invasion in human gastric carcinoma through downregulatedting SOX4. Oncol Lett. 14:3760–3766. 2017. View Article : Google Scholar : PubMed/NCBI
19	Zhao S, Gao X, Zang S, Li Y, Feng X and Yuan X: MicroRNA-383-5p acts as a prognostic marker and inhibitor of cell proliferation in lung adenocarcinoma by cancerous inhibitor of protein phosphatase 2A. Oncol Lett. 14:3573–3579. 2017. View Article : Google Scholar : PubMed/NCBI
20	Qiao W, Cao N and Yang L: MicroRNA-154 inhibits the growth and metastasis of gastric cancer cells by directly targeting MTDH. Oncol Lett. 14:3268–3274. 2017. View Article : Google Scholar : PubMed/NCBI
21	Song C, Lu P, Sun G, Yang L and Wang Z and Wang Z: miR-34a sensitizes lung cancer cells to cisplatin via p53/miR-34a/MYCN axis. Biochem Biophys Res Commun. 482:22–27. 2017. View Article : Google Scholar : PubMed/NCBI